Loading news...
Cinctive Capital Management LP trimmed its stake in BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 50.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 95,672 shares of the company's stock after selling 98,688 shares during the quarter. Cinctive
Limb-girdle muscular dystrophy type R9 (LGMDR9, formerly 2I) is a rare genetic disease caused by mutations in the FKRP gene.
BridgeBio Pharma, Inc. (BBIO) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
- Phase 3 FORTIFY interim analysis results presented in a late-breaking oral presentation at MDA highlight the broad and consistent efficacy of BBP-418 across key clinical endpoints and prespecified subgroups
BridgeBio stock popped Tuesday on a notable shake-up in the patent battle surrounding Pfizer's rival drug, tafamidis.
Victory Capital Management Inc. grew its position in shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 42.0% during the third quarter, according to its most recent filing with the SEC. The firm owned 479,680 shares of the company's stock after acquiring an additional 141,800 shares during the period. Victory Capital Management Inc. owned
BridgeBio Pharma (NASDAQ: BBIO) CEO Neil Kumar outlined the company's recent clinical progress, commercial momentum, and near-term regulatory plans during a fireside chat at TD Cowen's 46th Annual Healthcare Conference, while also addressing investor focus on a pending intellectual property trial related to tafamidis. Stock pullback and the tafamidis IP overhang Kumar said the company has
PALO ALTO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional data from the interim analysis of FORTIFY, the Phase 3 clinical trial of BBP-418 in patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), will be shared in a late-breaking oral presentation at the MDA Clinical and Scientific Conference, taking place in Orlando, Florida on March 8-11, 2026. Additionally, an oral presentation from BridgeBio's academic collaborators at Yale School of Medicine, along with four posters, will highlight advances in the understanding of BBP-418 and LGMD2I/R9.
BridgeBio Pharma (BBIO) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to a loss of $1.31 per share a year ago.
BridgeBio Pharma, Inc. (BBIO) Q4 2025 Earnings Call Transcript
PALO ALTO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today its financial results for the fourth quarter and full year ended December 31, 2025, and provided an update on Attruby's commercial progress.
BridgeBio Pharma, Inc. (NASDAQ: BBIO - Get Free Report) CEO Neil Kumar sold 28,053 shares of the firm's stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $71.39, for a total transaction of $2,002,703.67. Following the sale, the chief executive officer directly owned 234,451 shares of
PALO ALTO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in the following healthcare investor conferences:
Ten large-cap stocks sank last week as weak earnings, lowered guidance, analyst downgrades, and deal-related headlines weighed on shares.
BridgeBio Pharma, Inc. (NASDAQ: BBIO - Get Free Report) Director Randal Scott sold 10,000 shares of the company's stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $75.46, for a total transaction of $754,600.00. Following the sale, the director owned 11,589 shares in the company, valued
BIT Capital GmbH cut its position in BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 94.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,056 shares of the company's stock after selling 16,504 shares during the quarter. BIT Capital GmbH's
BridgeBio Pharma, Inc. (NASDAQ: BBIO - Get Free Report) CFO Thomas Trimarchi sold 13,600 shares of the company's stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $74.72, for a total value of $1,016,192.00. Following the sale, the chief financial officer owned 336,585 shares of the company's stock,
Oppenheimer and Co. Inc. acquired a new position in BridgeBio Pharma, Inc. (NASDAQ: BBIO) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 7,845 shares of the company's stock, valued at approximately $407,000. Several other large investors have also recently added to or
PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on February 12, 2026, the compensation committee of BridgeBio's board of directors approved equity grants to 34 new employees in restricted stock units for an aggregate of 76,701 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on February 16, 2027, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates.
PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its fourth quarter and full year 2025 financial results and business updates after the market closes on Tuesday, February 24, 2026.